Anne Moore

Professor Anne Moore completed a PhD in HIV vaccine immunology with Professor Kingston Mills. She subsequently embarked upon post-doctoral work on defects in immune responses in HIV-infected individuals in the Wistar Institute in Philadelphia and further work on recombinant vaccines against viruses such as HIV and Ebola virus in Dr. Gary Nabel’s lab, then at the University of Michigan. As a senior immunologist in Prof. Adrian Hill’s group in the University of Oxford, she developed several T cell inducing vaccine candidates against malaria, TB and influenza and was involved in clinical trials of these and other vaccine candidates. She lectured in Pharmacology in the School of Pharmacy, UCC from 2007 to 2018. In 2016 she worked with the vaccine biotech company, Vaxart, South San Francisco, while on sabbatical. Here she contributed to the development of oral vaccines for a range of therapeutic and prophylactic vaccines. She moved to the School of Biochemistry and Cell Biology, UCC In September 2018 and took up a joint position in UCC and in NIBRT in January 2024.

Prof. Moore’s research focus is to advance effective interventions to improve vaccine effectiveness, primarily by developing vaccine delivery technologies to address equitable access and acceptability needs and, secondarily, by understanding people’s acceptability of vaccines. Her research extends from basic immunology and vaccine formulation to clinical translation and vaccine acceptance and confidence. Some currently funded projects focus on understanding how the vaccine delivery technology impacts on the breadth of the immune response in a relevant large animal model; developing novel vaccines to tackle anti-microbial resistance and developing vaccine-based microarray patches for injection-free ease of use and ease of deployment.